HEALIUS LIMITED — Director's Dealing 2024

Mar 3, 2024

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maxine Jaquet
Date of last notice	31 January2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As shown
Date of change	28 February 2024
No. of securities held prior to change	521,161 Ordinary Shares 1,667,806 Options 371,859 Performance Rights
Class	Performance Rights
Number acquired	512,645
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights value of $2.926 per right calculated using 10 Day VWAP from 3 -14 July 2023.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

521,161 Ordinary Shares No. of securities held after 1,667,806 Options change 884,504 Performance Rights Nature of change Issue of performance rights under the Long-Term Example: on-market trade, off-market trade, exercise of options, issue of securities under Incentive Plan in accordance with shareholder approval dividend reinvestment plan, participation in buyobtained at HLS 2023 AGM. back

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where N/A prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date N/A was this provided?

Authorised by the Company Secretary.

Mary Weaver Company Secretary Date: 4 March 2024

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011